The best VC’s for developing Therapeutics in Europe?

The best VC’s for developing Therapeutics in Europe?

22/10/2020

The VC’s investing in Europe can be ranked by the number of times they have participated in a EUR >50M M&A of a company developing therapeutics. In Sunstone’s analysis of the 56 M&As that took place in the period 2010-2020, 243 named investors participated....
Beating the odds

Beating the odds

07/10/2020

What do you think? Let us know in our feed on LinkedIn:  Using Pitchbook® we have identified 56, EUR >50M, M&A transactions of VC funded companies developing therapeutics from 2010 to 2020 and have modelled the investor cash flow in each of the companies....

Cantargias valberedning föreslår ny styrelseledamot

22/09/2020

Cantargias valberedning föreslår ny styrelseledamot Valberedningen i Cantargia AB (publ), som består av Sten Verland (partner i Sunstone Life Science Ventures, ordförande), Jannis Kitsakis (Fjärde AP-fonden), Alexander Mata (Alecta Pensionförsäkring, ömsesidigt) och...

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020.

16/09/2020

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020. Orphazyme A/S (ORPHA.CO), a...